Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
Inoue S, Sassa N, Kawanishi H, Yuguchi Y, Suzuki T, Nagayama J, Matsui H, Miyata Y, Soeda Y, Tochigi K, Yamauchi Y, Maeda M, Kobayashi I, Hattori R, Matsukawa Y, Kato M.
Inoue S, et al. Among authors: hattori r.
Anticancer Res. 2022 Jul;42(7):3627-3636. doi: 10.21873/anticanres.15851.
Anticancer Res. 2022.
PMID: 35790259